Cargando…

Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351079/ https://www.ncbi.nlm.nih.gov/pubmed/25742303 http://dx.doi.org/10.1371/journal.pone.0119048

Ejemplares similares

EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
por: Terragni, Rossella, et al.
Publicado: (2014)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2020)

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
Publicado: (2022)

Correction: Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients
Publicado: (2014)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Correction: The Canine Oral Microbiome
por: Dewhirst, Floyd E., et al.
Publicado: (2012)

Correction to: Canine breeds associated with gastric carcinoma, metaplasia and dysplasia diagnosed by histopathology of endoscopic biopsy samples
por: Candido, Marcus Vinicius, et al.
Publicado: (2020)

Correction: Inactivation of TIF1γ Cooperates with Kras(G12D) to Induce Cystic Tumors of the Pancreas
por: Vincent, David F., et al.
Publicado: (2009)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
por: Kulemann, Birte, et al.
Publicado: (2017)

Correction: HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

Correction: Potential Role of Estrogen Receptor Beta as a Tumor Suppressor of Epithelial Ovarian Cancer
por: Bossard, Carine, et al.
Publicado: (2013)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Correction: p63 suppresses the ability of pregnancy-identified mammary epithelial cells (PIMECs) to drive HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Antitumor Activity of an Anti-EGFR/HER2 Bispecific Antibody in a Mouse Xenograft Model of Canine Osteosarcoma
por: Tateyama, Nami, et al.
Publicado: (2022)

Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials
Publicado: (2020)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

Correction: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
Publicado: (2019)

Correction: Expression profiling of disease progression in canine model of Duchenne muscular dystrophy
por: Brinkmeyer-Langford, Candice, et al.
Publicado: (2020)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Correction: modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors
por: Pedicini, Piernicola, et al.
Publicado: (2012)

Correction: Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
por: Ma, Jui-Wen, et al.
Publicado: (2019)

Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
por: Doyle, Hester A., et al.
Publicado: (2021)

Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”
por: Li, Chuan-Hong, et al.
Publicado: (2023)

Correction: Cell line-specific efficacy of thermoradiotherapy in human and canine cancer cells in vitro
Publicado: (2019)

HER-2 and EGFR mRNA Expression and Its Relationship with Versican in Malignant Matrix-Producing Tumors of the Canine Mammary Gland
por: Damasceno, Karine Araújo, et al.
Publicado: (2016)

Correction: An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer
por: Katz, Elad, et al.
Publicado: (2011)

Correction: An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer
por: Katz, Elad, et al.
Publicado: (2011)

Correction: An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer
por: Katz, Elad, et al.
Publicado: (2011)

Correction: An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer
por: Katz, Elad, et al.
Publicado: (2011)

Correction: An In Vitro Model That Recapitulates the Epithelial to Mesenchymal Transition (EMT) in Human Breast Cancer
por: Katz, Elad, et al.
Publicado: (2011)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_utkhrf95bbbjigi000gs8qskpo